Scrip
US panel backs Pfizer's Selzentry in treatment-naïve HIV
09 October 2009
Sue Sutter
Please Login to read the full article.
09 October 2009
Sue Sutter
A US
FDA advisory panel has endorsed adding an HIV treatment-naïve indication to
Pfizer's CCR5 antagonist Selzentry (maraviroc). In a 10 to four vote, the antiviral drugs advisory committee said safety, efficacy and resistance data support approval for combination treatment in HIV-1...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Dual Kaletra/Isentress HIV regimen looks as effective as traditional HAART
- Early HIV treatment reduces death rate by 75% in NEJM study
- ViiV's Selzentry approved for treatment-naive HIV patients in US
- J&J's HIV drug rilpivirine passes Phase III trials but stumbles on virologic failure
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
